| scholarly article | Q13442814 |
| P50 | author | Antonio Rosato | Q40676155 |
| Silvio Bicciato | Q42582584 | ||
| Sirio Dupont | Q50881440 | ||
| Michelangelo Cordenonsi | Q57120933 | ||
| Aldo Solari | Q58415311 | ||
| P2093 | author name string | Stefano Piccolo | |
| Vincenza Guzzardo | |||
| Allan Balmain | |||
| Maddalena Adorno | |||
| Byron Hann | |||
| Christine Wong | |||
| Sara Bobisse | |||
| Marco Montagner | |||
| Anna R Parenti | |||
| Maria Beatrice Rondina | |||
| P2860 | cites work | FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination | Q24315150 |
| Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications | Q27860709 | ||
| TGF-beta signaling in tumor suppression and cancer progression | Q29615427 | ||
| Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice | Q29617045 | ||
| Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis | Q30004190 | ||
| A progression puzzle | Q33337505 | ||
| Concordance among gene-expression-based predictors for breast cancer | Q34555829 | ||
| Assessing TP53 status in human tumours to evaluate clinical outcome | Q34570100 | ||
| Integration of TGF-beta and Ras/MAPK signaling through p53 phosphorylation. | Q34603719 | ||
| p63 and p73 in human cancer: defining the network | Q36749787 | ||
| Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. | Q38291171 | ||
| A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain | Q39458140 | ||
| An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations | Q40198133 | ||
| Links between tumor suppressors: p53 is required for TGF-beta gene responses by cooperating with Smads. | Q40649890 | ||
| TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice | Q45345227 | ||
| Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. | Q51929705 | ||
| Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. | Q52561781 | ||
| Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. | Q53376881 | ||
| Metastasis is driven by sequential elevation of H-ras and Smad2 levels. | Q54297451 | ||
| Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome | Q81166001 | ||
| Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family | Q81662172 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | transformation related protein 63 | Q15314027 |
| P304 | page(s) | 87-98 | |
| P577 | publication date | 2009-04-01 | |
| P1433 | published in | Cell | Q655814 |
| P1476 | title | A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis | |
| P478 | volume | 137 |
| Q37000533 | 15-hydroxyprostaglandin dehydrogenase-derived 15-keto-prostaglandin E2 inhibits cholangiocarcinoma cell growth through interaction with peroxisome proliferator-activated receptor-γ, SMAD2/3, and TAP63 proteins |
| Q36503015 | 8-Amino-adenosine activates p53-independent cell death of metastatic breast cancers |
| Q27316326 | A MAPK-Driven Feedback Loop Suppresses Rac Activity to Promote RhoA-Driven Cancer Cell Invasion |
| Q36636769 | A MicroRNA196a2* and TP63 circuit regulated by estrogen receptor-α and ERK2 that controls breast cancer proliferation and invasiveness properties |
| Q24312083 | A Pin1/mutant p53 axis promotes aggressiveness in breast cancer |
| Q90192681 | A Protein in the Yeast Saccharomyces cerevisiae Presents DNA Binding Homology to the p53 Checkpoint Protein and Tumor Suppressor |
| Q35106947 | A core invasiveness gene signature reflects epithelial-to-mesenchymal transition but not metastatic potential in breast cancer cell lines and tissue samples |
| Q47702782 | A double dealing tale of p63: an oncogene or a tumor suppressor |
| Q58695672 | A feed forward loop enforces YAP/TAZ signaling during tumorigenesis |
| Q33591375 | A genomewide study identifies the Wnt signaling pathway as a major target of p53 in murine embryonic stem cells |
| Q35739462 | A global analysis of the complex landscape of isoforms and regulatory networks of p63 in human cells and tissues. |
| Q35915947 | A microRNA circuit mediates transforming growth factor-β1 autoregulation in renal glomerular mesangial cells |
| Q33914753 | A multifactorial 'Consensus Signature' by in silico analysis to predict response to neoadjuvant anthracycline-based chemotherapy in triple-negative breast cancer. |
| Q35339915 | A mutant p53/let-7i-axis-regulated gene network drives cell migration, invasion and metastasis. |
| Q64992109 | A novel RNA aptamer identifies plasma membrane ATP synthase beta subunit as an early marker and therapeutic target in aggressive cancer. |
| Q35503722 | A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition. |
| Q42029826 | A rare DNA contact mutation in cancer confers p53 gain-of-function and tumor cell survival via TNFAIP8 induction. |
| Q41564767 | A signal-based method for finding driver modules of breast cancer metastasis to the lung. |
| Q38699698 | A truncated p53 in human lung cancer cells as a critical determinant of proliferation and invasiveness |
| Q37046703 | A20 inhibits the motility of HCC cells induced by TNF-α |
| Q38868164 | AP4 activates cell migration and EMT mediated by p53 in MDA-MB-231 breast carcinoma cells. |
| Q35724108 | ATM regulation of IL-8 links oxidative stress to cancer cell migration and invasion |
| Q92572423 | Aberrant NFATc1 signaling counteracts TGFβ-mediated growth arrest and apoptosis induction in pancreatic cancer progression |
| Q102369410 | Aberrant transcriptional and post-transcriptional regulation of SPAG5, a YAP-TAZ-TEAD downstream effector, fuels breast cancer cell proliferation |
| Q37132255 | Acetylation of the cell-fate factor dachshund determines p53 binding and signaling modules in breast cancer |
| Q35819661 | Aerobic glycolysis tunes YAP/TAZ transcriptional activity |
| Q34638529 | Allele-specific p53 mutant reactivation |
| Q36581678 | Alternatively spliced protein arginine methyltransferase 1 isoform PRMT1v2 promotes the survival and invasiveness of breast cancer cells. |
| Q83729340 | Anthracyclines induce the accumulation of mutant p53 through E2F1-dependent and -independent mechanisms |
| Q36562253 | Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations |
| Q27004250 | Anti-tumor activity of non-steroidal anti-inflammatory drugs: cyclooxygenase-independent targets |
| Q35128650 | Apoptosis, autophagy, necroptosis, and cancer metastasis |
| Q35891245 | Attenuation of TGF-β signaling suppresses premature senescence in a p21-dependent manner and promotes oncogenic Ras-mediated metastatic transformation in human mammary epithelial cells |
| Q28364357 | Automated Quantification and Analysis of Cell Counting Procedures Using ImageJ Plugins |
| Q37170604 | BRCA1/FANCD2/BRG1-Driven DNA Repair Stabilizes the Differentiation State of Human Mammary Epithelial Cells |
| Q36824242 | BSP gene silencing inhibits migration, invasion, and bone metastasis of MDA-MB-231BO human breast cancer cells |
| Q39344938 | BTG2 loss and miR-21 upregulation contribute to prostate cell transformation by inducing luminal markers expression and epithelial-mesenchymal transition. |
| Q46611970 | COX-2 inhibitor NS-398 suppresses doxorubicin-induced p53 accumulation through inhibition of ROS-mediated Jnk activation |
| Q37129887 | Cancer stem cells in breast cancer |
| Q38211598 | Casein kinase: the triple meaning of a misnomer |
| Q36907168 | Caspase-1 is a novel target of p63 in tumor suppression |
| Q24319946 | Cell density-dependent acetylation of ΔNp63α is associated with p53-dependent cell cycle arrest |
| Q33977102 | Characteristics and survival of patients with advanced cancer and p53 mutations |
| Q60931087 | Chemoresistance and the Self-Maintaining Tumor Microenvironment |
| Q34965421 | Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma |
| Q35014893 | Co-overexpression of GEP100 and AMAP1 proteins correlates with rapid local recurrence after breast conservative therapy |
| Q33633277 | Combining Oncolytic Virotherapy with p53 Tumor Suppressor Gene Therapy |
| Q35103336 | Comparison of effects of p53 null and gain-of-function mutations on salivary tumors in MMTV-Hras transgenic mice. |
| Q34760892 | Comparison of modules of wild type and mutant Huntingtin and TP53 protein interaction networks: implications in biological processes and functions |
| Q55333537 | Complexes formed by mutant p53 and their roles in breast cancer. |
| Q37508344 | Comprehensive phenotypic analysis of knockout mice deficient in cyclin G1 and cyclin G2. |
| Q37288325 | Computational identification of a p38SAPK-regulated transcription factor network required for tumor cell quiescence |
| Q57461758 | Consensus report of the 8 and 9th Weinman Symposia on Gene x Environment Interaction in carcinogenesis: novel opportunities for precision medicine |
| Q90699144 | Context is everything: extrinsic signalling and gain-of-function p53 mutants |
| Q33776331 | Contribution of p53 to metastasis |
| Q37075390 | Coordinate transcriptional and translational repression of p53 by TGF-β1 impairs the stress response |
| Q37151653 | Critical role of the WASF3 gene in JAK2/STAT3 regulation of cancer cell motility |
| Q38177887 | Crosstalk among p53 family members in cutaneous carcinoma. |
| Q41872966 | Crosstalk between p53 and TGF-β Signalling. |
| Q38112074 | Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme |
| Q58695035 | Cyclin G2 Suppresses Glomerulosclerosis by Regulating Canonical Wnt Signalling |
| Q37257711 | Cyclin G2 inhibits epithelial-to-mesenchymal transition by disrupting Wnt/β-catenin signaling |
| Q30009513 | Cyclin G2 promotes hypoxia-driven local invasion of glioblastoma by orchestrating cytoskeletal dynamics. |
| Q36796438 | Cyclins and cell cycle control in cancer and disease |
| Q34054835 | Cysteine-rich 61-connective tissue growth factor-nephroblastoma-overexpressed 5 (CCN5)/Wnt-1-induced signaling protein-2 (WISP-2) regulates microRNA-10b via hypoxia-inducible factor-1α-TWIST signaling networks in human breast cancer cells |
| Q40758235 | Delineating Molecular Mechanisms of Squamous Tissue Homeostasis and Neoplasia: Focus on p63. |
| Q48054648 | Detection of the tumour suppressor gene TP53 and expression of p53, Bcl-2 and p63 proteins in canine transmissible venereal tumour |
| Q35694156 | Diacylglycerol kinase α controls RCP-dependent integrin trafficking to promote invasive migration. |
| Q37109737 | Dicer suppresses the malignant phenotype in VHL-deficient clear cell renal cell carcinoma by inhibiting HIF-2α. |
| Q39027205 | Dichotomous roles of TGF-β in human cancer |
| Q47406043 | Distinct TP63 Isoform-Driven Transcriptional Signatures Predict Tumor Progression and Clinical Outcomes. |
| Q62057894 | Diverse and cancer type‑specific roles of the p53 R248Q gain‑of‑function mutation in cancer migration and invasiveness |
| Q91964954 | Do Mutations Turn p53 into an Oncogene? |
| Q34243896 | Dormancy signatures and metastasis in estrogen receptor positive and negative breast cancer |
| Q36406354 | Down-regulation of LATS kinases alters p53 to promote cell migration. |
| Q37770965 | Dynamics of microRNA biogenesis: crosstalk between p53 network and microRNA processing pathway. |
| Q38881935 | ELAS1-mediated inhibition of the cyclin G1-B'γ interaction promotes cancer cell apoptosis via stabilization and activation of p53. |
| Q35999401 | EMT and induction of miR-21 mediate metastasis development in Trp53-deficient tumours |
| Q35579435 | ERK1/2 and p38α/β signaling in tumor cell quiescence: opportunities to control dormant residual disease |
| Q37046414 | ERβ decreases the invasiveness of triple-negative breast cancer cells by regulating mutant p53 oncogenic function |
| Q42513341 | Early-Stage Metastasis Requires Mdm2 and Not p53 Gain of Function. |
| Q36080515 | Elevated cyclin G2 expression intersects with DNA damage checkpoint signaling and is required for a potent G2/M checkpoint arrest response to doxorubicin. |
| Q47164772 | Elevated expression of ΔNp63 in advanced esophageal squamous cell carcinoma |
| Q28077156 | Emerging Non-Canonical Functions and Regulation by p53: p53 and Stemness |
| Q37793651 | Emerging complexity of microRNA generation cascades. |
| Q37912219 | Emerging pathways and future targets for the molecular therapy of pancreatic cancer |
| Q41376475 | Epidermal growth factor receptor and mutant p53 expand an esophageal cellular subpopulation capable of epithelial-to-mesenchymal transition through ZEB transcription factors |
| Q36986452 | Epithelial-mesenchymal transition in breast cancer progression and metastasis |
| Q37701488 | ErbB2 inhibition by lapatinib promotes degradation of mutant p53 protein in cancer cells. |
| Q52569162 | Estrogen-induced miR-196a elevation promotes tumor growth and metastasis via targeting SPRED1 in breast cancer. |
| Q26827810 | Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds. |
| Q60340345 | Every step of the way: integrins in cancer progression and metastasis |
| Q39134087 | Exploiting the p53 Pathway for Therapy. |
| Q42018779 | Expression Patterns of Gli-1, Pleckstrin Homology-Like Domain, Family A, Member 1, Transforming Growth Factor-β1/β2, and p63 in Sebaceous and Follicular Tumors |
| Q35604194 | Fascin protein is critical for transforming growth factor β protein-induced invasion and filopodia formation in spindle-shaped tumor cells. |
| Q34402680 | Flipping the switch: integrin switching provides metastatic competence |
| Q39067507 | Forkhead transcription factor FOXF1 is a novel target gene of the p53 family and regulates cancer cell migration and invasiveness. |
| Q36379430 | Frequent alterations in cytoskeleton remodelling genes in primary and metastatic lung adenocarcinomas |
| Q64102183 | Functional Diversity of p53 in Human and Wild Animals |
| Q34989395 | Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells |
| Q39752535 | Functional interaction between Smad3 and S100A4 (metastatin-1) for TGF-beta-mediated cancer cell invasiveness |
| Q28910323 | Functional interplay between MDM2, p63/p73 and mutant p53 |
| Q39122658 | Functions of TAp63 and p53 in restraining the development of metastatic cancer. |
| Q55518834 | GDA, a web-based tool for Genomics and Drugs integrated analysis. |
| Q89805344 | Gain-of-Function Mutations in p53 in Cancer Invasiveness and Metastasis |
| Q47744553 | Gain-of-function mutant p53 activates small GTPase Rac1 through SUMOylation to promote tumor progression |
| Q50154920 | Genetic status of KRAS influences Transforming Growth Factor-beta (TGF-β) signaling: An insight into Neuropilin-1 (NRP1) mediated tumorigenesis |
| Q36180219 | Genome-wide analysis of p63 binding sites identifies AP-2 factors as co-regulators of epidermal differentiation |
| Q38844916 | Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth |
| Q40165187 | Genome-wide characterization reveals complex interplay between TP53 and TP63 in response to genotoxic stress |
| Q37598468 | Glucocorticoid receptor signalling activates YAP in breast cancer |
| Q37629962 | High iodine blocks a Notch/miR-19 loop activated by the BRAF(V600E) oncoprotein and restores the response to TGFβ in thyroid follicular cells. |
| Q36390683 | Histone modifications affect differential regulation of TGFβ- induced NADPH oxidase 4 (NOX4) by wild-type and mutant p53. |
| Q38184518 | How the TP53 family proteins TP63 and TP73 contribute to tumorigenesis: regulators and effectors |
| Q39267423 | HuR is necessary for mammary epithelial cell proliferation and polarity at least in part via ΔNp63. |
| Q92324279 | Hypoxia-induced feedback of HIF-1α and lncRNA-CF129 contributes to pancreatic cancer progression through stabilization of p53 protein |
| Q37428993 | Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model |
| Q47129006 | Identification and characterization of a metastatic suppressor BRMS1L as a target gene of p53. |
| Q36420175 | Impaired TGF-β induced growth inhibition contributes to the increased proliferation rate of neural stem cells harboring mutant p53 |
| Q33768778 | Impedimetric detection of mutant p53 biomarker-driven metastatic breast cancers under hyposmotic pressure |
| Q34488339 | In vivo regulation of TGF-β by R-Ras2 revealed through loss of the RasGAP protein NF1. |
| Q59792591 | Induction of immunosuppressive functions and NF-κB by FLIP in monocytes |
| Q37668231 | Inflammation and EMT: an alliance towards organ fibrosis and cancer progression |
| Q36732552 | Inflammation and Hras signaling control epithelial-mesenchymal transition during skin tumor progression. |
| Q35804221 | Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy |
| Q39505296 | Inhibition of p53 expression by peptide-conjugated phosphorodiamidate morpholino oligomers sensitizes human cancer cells to chemotherapeutic drugs. |
| Q28000133 | Interaction of p53 with the CCT complex promotes protein folding and wild-type p53 activity |
| Q36512511 | Intra-amniotic transient transduction of the periderm with a viral vector encoding TGFβ3 prevents cleft palate in Tgfβ3(-/-) mouse embryos |
| Q50284366 | Intrinsic aggregation propensity of the p63 and p73 TI domains correlates with p53R175H interaction and suggests further significance of aggregation events in the p53 family |
| Q38161336 | Involvement of COUP-TFs in Cancer Progression |
| Q91677426 | Irradiation induces p53 loss of heterozygosity in breast cancer expressing mutant p53 |
| Q43205198 | Isoform specific phosphorylation of p53 by protein kinase CK1. |
| Q36393067 | Key signaling nodes in mammary gland development and cancer: Smad signal integration in epithelial cell plasticity |
| Q43939834 | Lack of significant association between TGF-β1-590C/T polymorphism and breast cancer risk: a meta-analysis |
| Q48690318 | Li-Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53. |
| Q90116051 | Linking stemness with colorectal cancer initiation, progression, and therapy |
| Q26864033 | Links between mutant p53 and genomic instability |
| Q30525287 | Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer |
| Q94562087 | Loss of wild-type p53 promotes mutant p53-driven metastasis through acquisition of survival and tumor-initiating properties |
| Q52727524 | MYC-driven epigenetic reprogramming favors the onset of tumorigenesis by inducing a stem cell-like state. |
| Q38556654 | Maintaining epithelial stemness with p63. |
| Q37110158 | Metabolic Pathway Signatures Associated with Urinary Metabolite Biomarkers Differentiate Bladder Cancer Patients from Healthy Controls |
| Q37327366 | Metabolic pathways regulated by TAp73 in response to oxidative stress |
| Q90115642 | Metastatic components in colorectal cancer |
| Q36124250 | MicroRNA circuits in transforming growth factor-β actions and diabetic nephropathy. |
| Q37706077 | MicroRNA control of signal transduction |
| Q35965859 | MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function |
| Q37117127 | MicroRNA-20a-5p contributes to hepatic glycogen synthesis through targeting p63 to regulate p53 and PTEN expression |
| Q38244285 | MicroRNAs and p63 in epithelial stemness. |
| Q35907222 | MicroRNAs and the glomerulus |
| Q46180966 | Microarray analysis reveals increased expression of ΔNp63α in seborrhoeic keratosis |
| Q36450759 | Microenvironments dictating tumor cell dormancy |
| Q29620776 | Modulation of microRNA processing by p53 |
| Q52362244 | Molecular Mechanisms and Emerging Therapeutic Targets of Triple-Negative Breast Cancer Metastasis. |
| Q42103308 | Molecular dynamics of the full-length p53 monomer |
| Q33764406 | Monitoring the dynamics of clonal tumour evolution in vivo using secreted luciferases |
| Q89064775 | Murine double minute 2, a potential p53-independent regulator of liver cancer metastasis |
| Q57818338 | Mutant TP53 modulates metastasis of triple negative breast cancer through adenosine A2b receptor signaling |
| Q33818479 | Mutant TP53 posttranslational modifications: challenges and opportunities. |
| Q35522196 | Mutant p53 - Heat Shock Response Oncogenic Cooperation: A New Mechanism of Cancer Cell Survival |
| Q36775403 | Mutant p53 Amplifies Epidermal Growth Factor Receptor Family Signaling to Promote Mammary Tumorigenesis. |
| Q30354662 | Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers. |
| Q52848530 | Mutant p53 Together with TGFβ Signaling Influence Organ-Specific Hematogenous Colonization Patterns of Pancreatic Cancer. |
| Q60959628 | Mutant p53 as a guardian of the cancer cell |
| Q49791721 | Mutant p53 controls tumor metabolism and metastasis by regulating PGC-1α. |
| Q35914917 | Mutant p53 cooperates with ETS2 to promote etoposide resistance |
| Q34480997 | Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells |
| Q24302433 | Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway |
| Q35626150 | Mutant p53 disrupts role of ShcA protein in balancing Smad protein-dependent and -independent signaling activity of transforming growth factor-β (TGF-β). |
| Q34288205 | Mutant p53 drives invasion in breast tumors through up-regulation of miR-155. |
| Q39460398 | Mutant p53 drives multinucleation and invasion through a process that is suppressed by ANKRD11. |
| Q37725691 | Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor β signaling |
| Q30537354 | Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion |
| Q33687048 | Mutant p53 gain-of-function in cancer |
| Q64892305 | Mutant p53 in cancer therapy-the barrier or the path. |
| Q38197826 | Mutant p53 in cancer: new functions and therapeutic opportunities |
| Q93367358 | Mutant p53 in colon cancer |
| Q55026448 | Mutant p53 inhibits miRNA biogenesis by interfering with the microprocessor complex. |
| Q24337116 | Mutant p53 interactome identifies nardilysin as a p53R273H-specific binding partner that promotes invasion |
| Q39297236 | Mutant p53 is a transcriptional co-factor that binds to G-rich regulatory regions of active genes and generates transcriptional plasticity |
| Q92736081 | Mutant p53 on the Path to Metastasis |
| Q50217013 | Mutant p53 oncogenic functions in cancer stem cells are regulated by WIP through YAP/TAZ. |
| Q47107350 | Mutant p53 partners in crime |
| Q38959098 | Mutant p53 promotes epithelial-mesenchymal plasticity and enhances metastasis in mammary carcinomas of WAP-T mice |
| Q36292196 | Mutant p53 promotes ovarian cancer cell adhesion to mesothelial cells via integrin β4 and Akt signals |
| Q35561112 | Mutant p53 promotes tumor cell malignancy by both positive and negative regulation of the transforming growth factor β (TGF-β) pathway |
| Q30313610 | Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5. |
| Q42282841 | Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition. |
| Q39064013 | Mutant p53 regulates Dicer through p63-dependent and -independent mechanisms to promote an invasive phenotype |
| Q27333756 | Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition. |
| Q41490261 | Mutant p53 stimulates cell invasion through an interaction with Rad21 in human ovarian cancer cells |
| Q38709284 | Mutant p53 upregulates alpha-1 antitrypsin expression and promotes invasion in lung cancer. |
| Q39421527 | Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome |
| Q89944650 | Mutant p53-Associated Molecular Mechanisms of ROS Regulation in Cancer Cells |
| Q36293880 | Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF). |
| Q30572690 | Mutant p53-associated myosin-X upregulation promotes breast cancer invasion and metastasis. |
| Q26776020 | Mutant p53: Multiple Mechanisms Define Biologic Activity in Cancer |
| Q26770576 | Mutant p53: One, No One, and One Hundred Thousand |
| Q36070574 | Mutant p53: one name, many proteins |
| Q59801568 | Mutant p53s generate pro-invasive niches by influencing exosome podocalyxin levels |
| Q35107599 | Mutation or loss of p53 differentially modifies TGFβ action in ovarian cancer |
| Q102141804 | Mutational drivers of cancer cell migration and invasion |
| Q37903701 | Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis |
| Q39007820 | Neomorphic mutations create therapeutic challenges in cancer. |
| Q38417021 | New insight on the biological role of p53 protein as a tumor suppressor: re-evaluation of its clinical significance in triple-negative breast cancer |
| Q38036571 | New insights into p53 signaling and cancer cell response to DNA damage: implications for cancer therapy |
| Q34685830 | New plays in the p53 theater |
| Q49962911 | New therapeutic strategies to treat human cancers expressing mutant p53 proteins |
| Q24300910 | Nodal enhances the activity of FoxO3a and its synergistic interaction with Smads to regulate cyclin G2 transcription in ovarian cancer cells |
| Q46273393 | Non-oncogenic roles of TAp73: from multiciliogenesis to metabolism |
| Q41464948 | Notch and TGFβ form a reciprocal positive regulatory loop that suppresses murine prostate basal stem/progenitor cell activity |
| Q38884385 | Notch is a direct negative regulator of the DNA-damage response |
| Q37051481 | Notch4-dependent antagonism of canonical TGF-β1 signaling defines unique temporal fluctuations of SMAD3 activity in sheared proximal tubular epithelial cells |
| Q26777988 | Novel Implications of DNA Damage Response in Drug Resistance of Malignant Cancers Obtained from the Functional Interaction between p53 Family and RUNX2 |
| Q34399666 | Novel p63 target genes involved in paracrine signaling and keratinocyte differentiation. |
| Q36291156 | Nuclear iASPP may facilitate prostate cancer progression. |
| Q64238496 | On the influence of cannabinoids on cell morphology and motility of glioblastoma cells |
| Q26749382 | Oncogenic Intra-p53 Family Member Interactions in Human Cancers |
| Q38846785 | Oncogenic Mutant p53 Gain of Function Nourishes the Vicious Cycle of Tumor Development and Cancer Stem-Cell Formation |
| Q92999963 | Oncogenic RUNX3: A Link between p53 Deficiency and MYC Dysregulation |
| Q34632548 | Opposing roles for calcineurin and ATF3 in squamous skin cancer |
| Q39643653 | Overexpression of ΔNp63α induces a stem cell phenotype in MCF7 breast carcinoma cell line through the Notch pathway |
| Q27308938 | P53- and mevalonate pathway-driven malignancies require Arf6 for metastasis and drug resistance. |
| Q36998524 | P63 regulates tubular formation via epithelial-to-mesenchymal transition |
| Q57806356 | Palbociclib enhances activin-SMAD-induced cytostasis in estrogen receptor-positive breast cancer |
| Q100558751 | Pan-cancer analysis reveals TAp63-regulated oncogenic lncRNAs that promote cancer progression through AKT activation |
| Q38904824 | Pancreatic cancer biology and genetics from an evolutionary perspective |
| Q35545782 | Pathway Regulation of p63, a Director of Epithelial Cell Fate |
| Q92393013 | Phytochemicals inhibit migration of triple negative breast cancer cells by targeting kinase signaling |
| Q34002555 | Pla2g16 phospholipase mediates gain-of-function activities of mutant p53. |
| Q38390837 | Pluripotency transcription factors in the pathogenesis of colorectal cancer and implications for prognosis |
| Q35102562 | Pluripotent stem cell miRNAs and metastasis in invasive breast cancer |
| Q39047902 | Possible involvement of ΔNp63 downregulation in the invasion and metastasis of oral squamous cell carcinoma via induction of a mesenchymal phenotype |
| Q33899450 | Posttranslational modification of p53: cooperative integrators of function |
| Q92540082 | Prognostic Role of Epithelial-Mesenchymal Transition Markers "E-Cadherin, β-Catenin, ZEB1, ZEB2 and p63" in Bladder Carcinoma |
| Q37606424 | Prolyl-isomerase Pin1 controls normal and cancer stem cells of the breast. |
| Q35464382 | Promotion of cell migration by neural cell adhesion molecule (NCAM) is enhanced by PSA in a polysialyltransferase-specific manner |
| Q51679220 | Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer. |
| Q30276654 | Ral-Arf6 crosstalk regulates Ral dependent exocyst trafficking and anchorage independent growth signalling |
| Q42498067 | Ras and TGF-β signaling enhance cancer progression by promoting the ΔNp63 transcriptional program |
| Q39154755 | Recruitment of cyclin G2 to promyelocytic leukemia nuclear bodies promotes dephosphorylation of γH2AX following treatment with ionizing radiation |
| Q33724429 | Redox control of p53 in the transcriptional regulation of TGF-β1 target genes through SMAD cooperativity |
| Q39106423 | Reduced expression of bone morphogenetic protein receptor IA in pancreatic cancer is associated with a poor prognosis |
| Q96348276 | Regulating tumor suppressor genes: post-translational modifications |
| Q60637267 | Regulation of the interferon-gamma (IFN-γ) pathway by p63 and Δ133p53 isoform in different breast cancer subtypes |
| Q36836555 | Regulation of tumor cell dormancy by tissue microenvironments and autophagy. |
| Q90706140 | Regulators of Oncogenic Mutant TP53 Gain of Function |
| Q38076317 | Regulatory networks defining EMT during cancer initiation and progression |
| Q92876161 | Relevance of Non-Targeted Effects for Radiotherapy and Diagnostic Radiology; A Historical and Conceptual Analysis of Key Players |
| Q37346990 | Repression of p63 and induction of EMT by mutant Ras in mammary epithelial cells |
| Q38213115 | Restoring the tumour suppressive function of p53 as a parallel strategy in melanoma therapy. |
| Q37105454 | Ribophorin II regulates breast tumor initiation and metastasis through the functional suppression of GSK3β. |
| Q24632945 | Role of DeltaNp63gamma in epithelial to mesenchymal transition |
| Q37885217 | Role of Smads in TGFβ signaling |
| Q29615411 | Role of YAP/TAZ in mechanotransduction |
| Q36284945 | Role of p63 in Development, Tumorigenesis and Cancer Progression |
| Q37620665 | S100A2 is a BRCA1/p63 coregulated tumour suppressor gene with roles in the regulation of mutant p53 stability |
| Q35207366 | SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis |
| Q34288454 | SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors. |
| Q38702971 | SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells. |
| Q30844760 | SMIFH2 has effects on Formins and p53 that perturb the cell cytoskeleton |
| Q39021056 | STXBP4 Drives Tumor Growth and Is Associated with Poor Prognosis through PDGF Receptor Signaling in Lung Squamous Cell Carcinoma |
| Q37301684 | Setdb1, a novel interactor of ΔNp63, is involved in breast tumorigenesis |
| Q39350425 | Signaling crosstalk between TGFβ and Dishevelled/Par1b |
| Q27027835 | Small molecule compounds targeting the p53 pathway: are we finally making progress? |
| Q30498093 | Spatial regulation of RhoA activity during pancreatic cancer cell invasion driven by mutant p53 |
| Q37650965 | Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis |
| Q36909843 | Squamous Cell Cancers: A Unified Perspective on Biology and Genetics |
| Q28079488 | Switching Roles of TGF-β in Cancer Development: Implications for Therapeutic Target and Biomarker Studies |
| Q38755076 | Synergistic induction of apoptosis by combination treatment with mesupron and auranofin in human breast cancer cells |
| Q33591245 | Systematic functional perturbations uncover a prognostic genetic network driving human breast cancer |
| Q33618850 | Systematic screening of isogenic cancer cells identifies DUSP6 as context-specific synthetic lethal target in melanoma |
| Q37420163 | TAp63 regulates oncogenic miR-155 to mediate migration and tumour growth |
| Q33635271 | TAp63 suppresses mammary tumorigenesis through regulation of the Hippo pathway. |
| Q35149652 | TAp73 promotes anabolism |
| Q92458066 | TFEB-driven autophagy potentiates TGF-β induced migration in pancreatic cancer cells |
| Q33936542 | TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression |
| Q34384395 | TGF-beta induces serous borderline ovarian tumor cell invasion by activating EMT but triggers apoptosis in low-grade serous ovarian carcinoma cells. |
| Q90926980 | TGF-β Family Signaling Pathways in Cellular Dormancy |
| Q39155158 | TGF-β Family Signaling in Tumor Suppression and Cancer Progression. |
| Q37045293 | TGF-β induces acetylation of chromatin and of Ets-1 to alleviate repression of miR-192 in diabetic nephropathy |
| Q37880676 | TGF-β signal transduction spreading to a wider field: a broad variety of mechanisms for context-dependent effects of TGF-β. |
| Q38796618 | TGF-β signaling in liver and gastrointestinal cancers |
| Q33355832 | TGF-β signaling in myeloid cells is required for tumor metastasis |
| Q36297071 | TGF-β-Induced Transcription Sustains Amoeboid Melanoma Migration and Dissemination. |
| Q85037287 | TGF-β1 29T/C polymorphism and breast cancer risk: a meta-analysis involving 25,996 subjects |
| Q35273414 | TGF-β1 induces epigenetic silence of TIP30 to promote tumor metastasis in esophageal carcinoma |
| Q37741025 | TGFbeta and cancer metastasis: an inflammation link. |
| Q37760038 | TGFbeta signalling: a complex web in cancer progression |
| Q28083107 | TGFβ Signaling in Tumor Initiation, Epithelial-to-Mesenchymal Transition, and Metastasis |
| Q37344716 | TP53 drives invasion through expression of its Δ133p53β variant |
| Q38180665 | TP53 mutants in the tower of babel of cancer progression |
| Q64937484 | TP53 mutations in epithelial ovarian cancer. |
| Q39530174 | TP63 P2 promoter functional analysis identifies β-catenin as a key regulator of ΔNp63 expression |
| Q46408321 | TP63 mutations are frequent in cutaneous melanoma, support UV etiology, but their role in melanomagenesis is unclear. |
| Q36035358 | Targeted Knockdown of the Kinetochore Protein D40/Knl-1 Inhibits Human Cancer in a p53 Status-Independent Manner |
| Q36476219 | Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer |
| Q38378172 | Targeted next-generation sequencing identifies molecular subgroups in squamous cell carcinoma of the head and neck with distinct outcome after concurrent chemoradiation |
| Q35937934 | Targeting IL13Ralpha2 activates STAT6-TP63 pathway to suppress breast cancer lung metastasis |
| Q27012443 | Targeting TGF-β signaling in cancer |
| Q38838071 | Targeting cellular and molecular drivers of head and neck squamous cell carcinoma: current options and emerging perspectives. |
| Q38997351 | Targeting mutant p53 in cancer: a long road to precision therapy. |
| Q36000813 | Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy. |
| Q91643844 | Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors |
| Q43051079 | Temozolomide suppresses MYC via activation of TAp63 to inhibit progression of human glioblastoma |
| Q36581657 | The "Sharp" blade against HIF-mediated metastasis. |
| Q35677720 | The BMP pathway either enhances or inhibits the Wnt pathway depending on the SMAD4 and p53 status in CRC. |
| Q26772237 | The Contrived Mutant p53 Oncogene - Beyond Loss of Functions |
| Q91816686 | The Diverse Functions of Mutant 53, Its Family Members and Isoforms in Cancer |
| Q42323049 | The Evolution of TP53 Mutations: From Loss-of-Function to Separation-of-Function Mutants |
| Q42397956 | The Expression Levels of XLF and Mutant P53 Are Inversely Correlated in Head and Neck Cancer Cells. |
| Q24296824 | The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells |
| Q28078288 | The Regulation of Tumor Suppressor p63 by the Ubiquitin-Proteasome System |
| Q37225303 | The consequence of oncomorphic TP53 mutations in ovarian cancer |
| Q37780777 | The crosstalk of RAS with the TGF-β family during carcinoma progression and its implications for targeted cancer therapy |
| Q36414431 | The downregulation of ΔNp63 in p53-deficient mouse epidermal tumors favors metastatic behavior |
| Q37602507 | The expanding universe of p53 targets |
| Q34472128 | The expression and clinical significance of ribophorin II (RPN2) in human breast cancer |
| Q39726023 | The expression of p33(ING1), p53, and autophagy-related gene Beclin1 in patients with non-small cell lung cancer |
| Q37797944 | The guardians of the genome (p53, TA-p73, and TA-p63) are regulators of tumor suppressor miRNAs network |
| Q38109711 | The impact of age on oncogenic potential: tumor-initiating cells and the brain microenvironment |
| Q28388257 | The impact of low-dose carcinogens and environmental disruptors on tissue invasion and metastasis |
| Q36972016 | The metastasis-promoting roles of tumor-associated immune cells |
| Q38170025 | The microRNA networks of TGFβ signaling in cancer |
| Q51281633 | The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumourigenesis. |
| Q39316123 | The p63 protein isoform ΔNp63α modulates Y-box binding protein 1 in its subcellular distribution and regulation of cell survival and motility genes. |
| Q38172403 | The physical basis of renal fibrosis: effects of altered hydrodynamic forces on kidney homeostasis |
| Q42342102 | The propensity for epithelial-mesenchymal transitions is dictated by chromatin states in the cancer cell of origin |
| Q27686765 | The rebel angel: mutant p53 as the driving oncogene in breast cancer |
| Q52805099 | The role of Next-Generation Sequencing in tumoral radiosensitivity prediction. |
| Q89460168 | The role of TP53 gain-of-function mutation in multifocal glioblastoma |
| Q34505037 | The role of epithelial plasticity in prostate cancer dissemination and treatment resistance |
| Q34153014 | The role of mutant p53 in human cancer |
| Q37858470 | The role of p63 in cancer, stem cells and cancer stem cells. |
| Q33607396 | The tale of transforming growth factor-beta (TGFbeta) signaling: a soigné enigma. |
| Q38029132 | The ubiquitin-proteasome system and signal transduction pathways regulating Epithelial Mesenchymal transition of cancer |
| Q63407187 | Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion |
| Q37815132 | Tracing the origins of metastasis |
| Q39005896 | Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53. |
| Q64958992 | Transcriptional addiction in cancer cells is mediated by YAP/TAZ through BRD4. |
| Q26992024 | Transcriptional control of cancer metastasis |
| Q90470180 | Transcriptional suppression of AMPKα1 promotes breast cancer metastasis upon oncogene activation |
| Q53626126 | Transcriptome and proteome of human hepatocellular carcinoma reveal shared metastatic pathways with significant genes. |
| Q36080368 | Transforming growth factor β1 (TGF-β1) suppresses growth of B-cell lymphoma cells by p14(ARF)-dependent regulation of mutant p53. |
| Q42563471 | Transforming growth factor-beta and mutant p53 conspire to induce metastasis by antagonizing p63: a (ternary) complex affair |
| Q34789300 | Transforming growth factor-β and the hallmarks of cancer |
| Q39380641 | Transforming growth factor-β enhances invasion and metastasis in Ras-transfected human malignant epidermal keratinocytes |
| Q37916975 | Transforming growth factor-β in the gastrointestinal and hepatic tumor microenvironment. |
| Q34037104 | Transitions between epithelial and mesenchymal states during cell fate conversions |
| Q49186604 | Treatment-associated TP53 DNA-binding domain missense mutations in the pathogenesis of secondary gliosarcoma |
| Q38259322 | Triple-negative breast cancer: investigating potential molecular therapeutic target |
| Q37728585 | Tumor microenvironment: driving forces and potential therapeutic targets for breast cancer metastasis |
| Q39201405 | Tumor suppressor WWOX binds to ΔNp63α and sensitizes cancer cells to chemotherapy |
| Q37591937 | Tumour suppression by p53: a role for the DNA damage response? |
| Q64265033 | Tyrosine Kinase Inhibitor Imatinib Mesylate Alters DMBA-Induced Early Onco/Suppressor Gene Expression with Tissue-Specificity in Mice |
| Q24338646 | USP15 is a deubiquitylating enzyme for receptor-activated SMADs |
| Q84393677 | USP4 is regulated by AKT phosphorylation and directly deubiquitylates TGF-β type I receptor |
| Q37802195 | Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies |
| Q37720633 | WASF3 regulates miR-200 inactivation by ZEB1 through suppression of KISS1 leading to increased invasiveness in breast cancer cells |
| Q55456858 | WIP-YAP/TAZ as A New Pro-Oncogenic Pathway in Glioma. |
| Q33613596 | Wild-type and mutant p53 differentially regulate NADPH oxidase 4 in TGF-β-mediated migration of human lung and breast epithelial cells |
| Q35180856 | Wild-type p53 controls cell motility and invasion by dual regulation of MET expression |
| Q42466219 | Wild-type p53 inhibits pro-invasive properties of TGF-β3 in breast cancer, in part through regulation of EPHB2, a new TGF-β target gene |
| Q37623308 | YAP enhances the pro-proliferative transcriptional activity of mutant p53 proteins |
| Q84991066 | You can win by losing: p53 mutations in rhabdomyosarcomas |
| Q37306553 | ZEB1 induces EPB41L5 in the cancer mesenchymal program that drives ARF6-based invasion, metastasis and drug resistance |
| Q51787888 | [The two faces of p63, Janus of the p53 gene family]. |
| Q37684429 | c-Abl inhibits breast cancer tumorigenesis through reactivation of p53-mediated p21 expression |
| Q53695910 | dNTP metabolism links mechanical cues and YAP/TAZ to cell growth and oncogene-induced senescence. |
| Q47786478 | miR-122 promotes metastasis of clear-cell renal cell carcinoma by downregulating Dicer |
| Q64251972 | miR-590-3p Targets Cyclin G2 and FOXO3 to Promote Ovarian Cancer Cell Proliferation, Invasion, and Spheroid Formation |
| Q34832663 | microRNAs: short non-coding bullets of gain of function mutant p53 proteins |
| Q33553472 | p130Cas is required for mammary tumor growth and transforming growth factor-beta-mediated metastasis through regulation of Smad2/3 activity. |
| Q34377287 | p53 Family and Cellular Stress Responses in Cancer |
| Q35326348 | p53 Family: Role of Protein Isoforms in Human Cancer |
| Q28079390 | p53 Proteoforms and Intrinsic Disorder: An Illustration of the Protein Structure-Function Continuum Concept |
| Q84583329 | p53 ancestry: gazing through an evolutionary lens |
| Q37832072 | p53 and its mutants in tumor cell migration and invasion |
| Q35434538 | p53 and ΔNp63α Coregulate the Transcriptional and Cellular Response to TGFβ and BMP Signals |
| Q50332171 | p53 gain-of-function mutations promote metastasis via ENTPD5 upregulation and enhanced N-glycoprotein folding. |
| Q33358202 | p53 in cell invasion, podosomes, and invadopodia |
| Q38069463 | p53 mutations in cancer |
| Q35032943 | p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase |
| Q38553239 | p53 regulates cytoskeleton remodeling to suppress tumor progression |
| Q34393678 | p53 status in stromal fibroblasts modulates tumor growth in an SDF1-dependent manner. |
| Q89783061 | p53's Extended Reach: The Mutant p53 Secretome |
| Q37727778 | p53-family proteins and their regulators: hubs and spokes in tumor suppression |
| Q91672818 | p53: Multiple Facets of a Rubik's Cube |
| Q39912973 | p53MutaGene: an online tool to estimate the effect of p53 mutational status on gene regulation in cancer. |
| Q40238287 | p63 and IRF6: brothers in arms against cleft palate |
| Q34080237 | p63 and p73, the ancestors of p53. |
| Q92493122 | p63 at the Crossroads between Stemness and Metastasis in Breast Cancer |
| Q35227440 | p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53. |
| Q39168509 | p63 regulates glutaminase 2 expression. |
| Q35774033 | p63 regulates human keratinocyte proliferation via MYC-regulated gene network and differentiation commitment through cell adhesion-related gene network |
| Q34273826 | p63 steps into the limelight: crucial roles in the suppression of tumorigenesis and metastasis |
| Q36078959 | p63 supports aerobic respiration through hexokinase II. |
| Q33576855 | p63 transcriptionally regulates the expression of matrix metallopeptidase 13. |
| Q37862578 | p63, a story of mice and men. |
| Q35709311 | p63-microRNA feedback in keratinocyte senescence |
| Q28611414 | p73 as a pharmaceutical target for cancer therapy |
| Q37413645 | {alpha}7 nicotinic acetylcholine receptor regulates airway epithelium differentiation by controlling basal cell proliferation. |
| Q36051831 | ΔNp63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer |
| Q36963424 | ΔNp63α Silences a miRNA Program to Aberrantly Initiate a Wound-Healing Program That Promotes TGFβ-Induced Metastasis |
| Q36179548 | ΔNp63α activates CD82 metastasis suppressor to inhibit cancer cell invasion |
| Q28077508 | ΔNp63α and microRNAs: leveraging the epithelial-mesenchymal transition |
| Q90426573 | ΔNp63α exerts antitumor functions in cervical squamous cell carcinoma |
| Q36159875 | ΔNp63α expression induces loss of cell adhesion in triple-negative breast cancer cells |
| Q38809040 | ΔNp63α induces quiescence and downregulates the BRCA1 pathway in estrogen receptor-positive luminal breast cancer cell line MCF7 but not in other breast cancer cell lines. |
| Q41958633 | ΔNp63α is an oncogene that targets chromatin remodeler Lsh to drive skin stem cell proliferation and tumorigenesis |
| Q42367820 | ΔNp63α modulates histone methyl transferase SETDB1 to transcriptionally repress target genes in cancers |
| Q37656142 | ΔNp63α regulates Erk signaling via MKP3 to inhibit cancer metastasis |
| Q27310096 | α5β1 integrin recycling promotes Arp2/3-independent cancer cell invasion via the formin FHOD3. |
| Q33688548 | ∆N-P63α and TA-P63α exhibit intrinsic differences in transactivation specificities that depend on distinct features of DNA target sites |
| Q94076800 | 子宫颈鳞状细胞癌中△Np63α、DPC4/Smad4和P21的表达及其临床意义 |
Search more.